The Soreq Applied Research Accelerator Facility (SARAF) - Overview, Research Programs and Future Plans

The Soreq Applied Research Accelerator Facility (SARAF) is under construction in the Soreq Nuclear Research Center at Yavne, Israel. When completed at the beginning of the next decade, SARAF will be a user facility for basic and applied nuclear physics, based on a 40 MeV, 5 mA CW proton/deuteron superconducting linear accelerator. Phase I of SARAF (SARAF-I, 4 MeV, 2 mA CW protons, 5 MeV 1 mA CW deuterons) is already in operation, generating scientific results in several fields of interest. The main ongoing program at SARAF-I is the production of 30 keV neutrons and measurement of Maxwellian Averaged Cross Sections (MACS), important for the astrophysical s-process. The world leading Maxwellian epithermal neutron yield at SARAF-I ($5\times 10^{10}$ epithermal neutrons/sec), generated by a novel Liquid-Lithium Target (LiLiT), enables improved precision of known MACSs, and new measurements of low-abundance and radioactive isotopes. Research plans for SARAF-II span several disciplines: Precision studies of beyond-Standard-Model effects by trapping light exotic radioisotopes, such as $^6$He, $^8$Li and $^{18,19,23}$Ne, in unprecedented amounts (including meaningful studies already at SARAF-I); extended nuclear astrophysics research with higher energy neutrons, including generation and studies of exotic neutron-rich isotopes relevant to the rapid (r-) process; nuclear structure of exotic isotopes; high energy neutron cross sections for basic nuclear physics and material science research, including neutron induced radiation damage; neutron based imaging and therapy; and novel radiopharmaceuticals development and production. In this paper we present a technical overview of SARAF-I and II, including a description of the accelerator and its irradiation targets; a survey of existing research programs at SARAF-I; and the research potential at the completed facility (SARAF-II).Comment: 32 pages, 31 figures, 10 tables, submitted as an invited review to European Physics Journal

The Mechanical Behavior of HAVAR Foils Using the Small Punch Technique

Prediction of the mechanical behavior of thin foils (~25 µm) requires special characterization techniques. The current work is focused on the mechanical and microstructural characterization of 25 µm HAVAR alloy foils following annealing, cold rolling, and subsequent heat treatments, using small punch testing (SPT), X-ray diffraction (XRD), and transmission-scanning electron microscopy (TEM). The SPT technique revealed that the annealed specimens exhibited the largest maximal load to failure and deformation (more than two-fold), compared to the cold rolled and heat treated conditions. The microscopy observations revealed high dislocation density following cold rolling and subsequent heat treatments. Following annealing, a cubic crystallographic structure (FCC) with equiaxed grains and a limited dislocation population was observed. Following cold rolling and subsequent thermal treatment, a preferred orientation texture (i.e., ‘deformation texture’) was observed with a very high dislocation density. The correlation between the mechanical behavior and the microstructural observations is discussed in detail

A 50 kW Liquid-Lithium Target for BNCT and Material-Science Applications

A compact Liquid Lithium Target (LiLiT) has been operating at SARAF for several years with beam power of several kW (1.9-2.5 MeV, up to 2 mA). When bombarding the lithium with low energy protons neutrons are generated. The neutron source, mainly used for nuclear astrophysics research, was decommissioned in 2016 towards an upgraded model - with possible applications to Boron Neutron Capture Therapy (BNCT) and material-science studies. The improved version has been designed to sustain 50 kW proton beam power (2.5 MeV, ~20 mA) to provide sufficient neutron flux required for clinical BNCT application. The new model has a 50 mm wide lithium jet to enable dissipation of the higher beam power and an improved heat exchanger to remove the power to a secondary cooling loop. A new Annular Linear INduction electro-magnetic pump (ALIN) has been designed and built to provide the required lithium flow rate. Other mechanical improvements facilitate the maintenance of the system and the robustness of operation. Radiological risks due to the 7Be produced in the reaction are reduced by using an integrated lead shielding of the lithium reservoir. An integrated neutron moderator is being designed to adjust the neutron energy to the spectrum best suited to BNCT. A low power (6 kW) model of the new design with a narrower nozzle (18 mm wide) and a rotating-magnet electro-magnetic pump is operating at SARAF to support the ongoing astrophysics and nuclear research program [1], [2]. To fulfill clinical BNCT, the upgraded LiLiT model will require an accelerator of appropriate energy and intensity. The design features of the new system are presented in this paper

A 50 kW Liquid-Lithium Target for BNCT and Material-Science Applications

A compact Liquid Lithium Target (LiLiT) has been operating at SARAF for several years with beam power of several kW (1.9-2.5 MeV, up to 2 mA). When bombarding the lithium with low energy protons neutrons are generated. The neutron source, mainly used for nuclear astrophysics research, was decommissioned in 2016 towards an upgraded model - with possible applications to Boron Neutron Capture Therapy (BNCT) and material-science studies. The improved version has been designed to sustain 50 kW proton beam power (2.5 MeV, ~20 mA) to provide sufficient neutron flux required for clinical BNCT application. The new model has a 50 mm wide lithium jet to enable dissipation of the higher beam power and an improved heat exchanger to remove the power to a secondary cooling loop. A new Annular Linear INduction electro-magnetic pump (ALIN) has been designed and built to provide the required lithium flow rate. Other mechanical improvements facilitate the maintenance of the system and the robustness of operation. Radiological risks due to the 7Be produced in the reaction are reduced by using an integrated lead shielding of the lithium reservoir. An integrated neutron moderator is being designed to adjust the neutron energy to the spectrum best suited to BNCT. A low power (6 kW) model of the new design with a narrower nozzle (18 mm wide) and a rotating-magnet electro-magnetic pump is operating at SARAF to support the ongoing astrophysics and nuclear research program [1], [2]. To fulfill clinical BNCT, the upgraded LiLiT model will require an accelerator of appropriate energy and intensity. The design features of the new system are presented in this paper

Reactions along the astrophysical s-process path and prospects for neutron radiotherapy with the Liquid-Lithium Target (LiLiT) at the Soreq Applied Research Accelerator Facility (SARAF)

Neutrons play a dominant role in the stellar nucleosynthesis of heavy elements and the quest for accurate experimental determinations of neutron-induced reaction cross sections becomes more stringent with the refinement of nuclear and astrophysical models. We review here an experimental nuclear-astrophysics program using a high-intensity neutron source based on the 7Li(p, n)7Be reaction with a Liquid-Lithium Target (LiLiT) at the Soreq Applied Research Accelerator Facility (SARAF) Phase I. The quasi-Maxwellian neutron spectrum with effective thermal energy $kT \approx 30$ keV, characteristic of the thick-target 7Li(p, n) yield at proton energy $E_p \approx 1.92$ MeV close to its neutron threshold, is well suited for laboratory measurements of neutron capture reactions along the astrophysical s -process path. The high-intensity proton beam (in the mA range) of SARAF and the high power (few kW) dissipation of LiLiT result in the most intense source of neutrons available today at stellar-like energies. The principle, design and properties of the LiLiT device and recent measurements of Maxwellian Averaged Cross Sections (MACS) based on activation of targets of astrophysical interest are described. Decay counting or atom counting methods (accelerator mass spectrometry, atom-trap trace analysis) are used for the detection of short-lived or long-lived activation products, respectively. In a different realm of applications, the 7Li(p, n) reaction is a leading candidate as an accelerator-based neutron source for Boron Neutron Capture Therapy (BNCT). The high neutron yield achievable from a liquid-lithium target, its sustainability of operation under kW-power incident beams and the recent availability of small-size high-intensity accelerators are compatible with a hospital-based clinical facility. An effort towards the characterization and realization of a liquid-lithium target for BNCT is reviewed. Perspectives of pending and future developments towards SARAF Phase II, based on a 40MeV, 5mA CW proton/deuteron superconducting linear accelerator, are summarized

Commissioning of New SARAF RFQ and Design of New Linac

International audienceSoreq Nuclear Research Center (SNRC) and CEA collaborate for the upgrade of the existing Soreq Applied Research Accelerator Facility (SARAF) accelerator up to 5mA Continuous Wave (CW) 40 MeV deuteron and proton beams (Phase 2). SNRC is upgrading the injector: the ion source, the low energy beam transport line and the 4-rods Radio Frequency Quadrupole (RFQ). CEA is in charge of the development and commissioning of the medium energy beam transport line and the superconducting linac. This paper presents the status of the SARAF linac development by CEA and the installation and testing of a new set of rods electrodes in the SARAF RFQ

Plasma Levels of C-Type Lectin REG3α and Gut Damage in People With Human Immunodeficiency Virus

BACKGROUND: Regenerating islet-derived protein 3α (REG3α) is an antimicrobial peptide secreted by intestinal Paneth cells. Circulating REG3α has been identified as a gut damage marker in inflammatory bowel diseases. People living with human immunodeficiency virus (PWH) on antiretroviral therapy (ART) present with an abnormal intestinal landscape leading to microbial translocation, persistent inflammation, and development of non-AIDS comorbidities. Herein, we assessed REG3α as a marker of gut damage in PWH. METHODS: Plasma from 169 adult PWH, including 30 elite controllers (ECs), and 30 human immunodeficiency virus (HIV)-uninfected controls were assessed. REG3α plasma levels were compared with HIV disease progression, epithelial gut damage, microbial translocation, and immune activation markers. RESULTS: Cross-sectionally, REG3α levels were elevated in untreated and ART-treated PWH compared with controls. ECs also had elevated REG3α levels compared to controls. Longitudinally, REG3α levels increased in PWH without ART and decreased in those who initiated ART. REG3α levels were inversely associated with CD4 T-cell count and CD4:CD8 ratio, while positively correlated with HIV viral load in untreated participants, and with fungal product translocation and inflammatory markers in all PWH. CONCLUSIONS: Plasma REG3α levels were elevated in PWH, including ECs. The gut inflammatory marker REG3α may be used to evaluate therapeutic interventions and predict non-AIDS comorbidity risks in PWH